APLS Apellis Pharmaceuticals

Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need

Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need
EN
05/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Apellis Pharmaceuticals

 PRESS RELEASE

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan inj...

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with SYFOVRE® (pegcetacoplan injection), the leading treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The results demonstrate that both every-other-month and monthly SYFOVRE delayed GA lesion growth by ap...

 PRESS RELEASE

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Confe...

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 2:40 p.m. ET. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s . A replay of the webcast will be available for approximately 90 days following the event. About ApellisApellis Pharmaceuticals, Inc. is a global biop...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch